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Numerous in vitro studies attribute to human TRIM5α some modest anti-HIV-1 activity and human
population studies suggest some differential effect of TRIM5α polymorphisms on disease progression.
If the activity of TRIM5α were relevant in vivo, it could result in positive selection on the viral capsid.
To address this issue, we identiﬁed 10 positively selected sites in HIV-1 capsid from multiple viral strains
and generated 17 clade B viruses carrying a minor (i.e. low frequency) residue or an alanine at those
positions. All recombinant viruses were susceptible to the modest effect of common human TRIM5α and
allelic variants R136Q, and H419Y; H43Y and G249D TRIM5α were generally inactive. Increased
sensitivity to TRIM5α was observed for some capsid variants, suggesting that minor residues are selected
against in human populations. On the other hand, the modest potency of human TRIM5α does not
translate in escape mutations in the viral capsid.
& 2013 Elsevier Inc. All rights reserved.Introduction
Human immunodeﬁciency virus type 1 (HIV-1) has a great
potential for adaptation as a result of genetic variability due to
high mutation rates, recombination events and short generation
times (Ho et al., 1995; Mansky, 1998; Zhuang et al., 2002). Between
hosts, evolution of HIV-1 is primarily shaped by neutral selection
associated with stochastic events; within hosts, HIV-1 is subjected
to natural selection mediated by diverse selective forces (Rambaut
et al., 2004). On one hand, constraining forces are exerted at the
RNA and protein level to preserve viral ﬁtness, therefore limiting
the plasticity of the HIV-1 genome (Holmes, 2003; Sanjuan and
Borderia, 2011; Snoeck et al., 2011; Woo et al., 2010). On the other
hand, immune response and drugs impose positive selection on
HIV-1 leading to the emergence of viral escape mutants (Snoeck
et al., 2011; Telenti, 2005). HIV-1 escape mutants are generated in
response to adaptive immune defense mediated by antibodies,
cytotoxic T lymphocytes (CTL) and to a lesser extent by T helper
lymphocytes (Goulder and Watkins, 2008; Henn et al., 2012;
Meddows-Taylor et al., 2004; Paul and Piontkivska, 2010;
Richman et al., 2003; Wei et al., 2003). Recently, killer inhibitoryll rights reserved.
of Microbiology, CHUV,
z),
ch (A. Telenti).receptors (KIR) from natural killer cells were also shown to exert
pressure on HIV-1 and to induce escape mutants (Alter et al.,
2011). The identiﬁcation of positively selected sites outside recog-
nized antibody, CTL and helper epitopes suggests that HIV-1 may
be exposed to other selective pressures such as innate immunity
host factors (Snoeck et al., 2011).
The restriction factor tripartite motif 5 alpha (TRIM5α) targets
lentiviruses in a species-speciﬁc manner through recognition of the
capsid (CA) (Stremlau et al., 2004b). Rhesus macaques express allelic
forms of TRIM5α, i.e. TRIM5TFP (TFP339-341), TRIM5Q (Q339) and
TRIM5CypA, that restrict efﬁciently HIV-1 and provide different
degrees of protection from infection by simian immunodeﬁciency
viruses (SIV) (Kirmaier et al., 2010; Newman et al., 2006). In parti-
cular, TRIM5TFP and TRIM5CypA alleles protect against cross-species
transmission of SIV from the Sooty Mangabey (SIVsm) and these
protective alleles are associated with the selection of escape CA
mutations (Kirmaier et al., 2010). The rhesus TRIM5α variants retain
some modest antiviral activity—2- to 3-fold at most—against the
adapted SIVmac239 and SIVmac251 strains in vitro (Kirmaier et al.,
2010; Lim et al., 2010; Newman et al., 2006; Stremlau et al., 2004b).
Rhesus macaques carrying two protective TRIM5TFP alleles present
lower viral loads of SIVmac251, less depletion of CD4+T cells and a
higher survival rate than TRIM5Q homozygous macaques (Letvin
et al., 2011; Lim et al., 2010).
A modest 2- to 3-fold activity of human TRIM5α against HIV-1
can also be observed in vitro by overexpressing human TRIM5α in
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et al., 2006; Song et al., 2005; Stremlau et al., 2004a) and in
primary CD4 cells (Richardson et al., 2008). Knock down of
endogenous TRIM5α in human cells results in diminished restric-
tion (Sebastian et al., 2006; Sokolskaja et al., 2006). Primary HIV-1
isolates have been identiﬁed that display increased sensitivity to
human TRIM5α-mediated restriction (Battivelli et al., 2010;
Kaumanns et al., 2006). There is controversy about the ability of
several human TRIM5 alleles to inﬂuence disease progression
in vivo (Goldschmidt et al., 2006; Javanbakht et al., 2006; Liu
et al., 2011; Nakajima et al., 2009; Price et al., 2010; Rahm and
Telenti, 2012; Sawyer et al., 2006; Speelmon et al., 2006; van
Manen et al., 2008).
If the activity of TRIM5α were important in vivo, or if different
human alleles differed in restricting capacity, these could translate
in the selection of escape variants in HIV-1. Positive selection
pressure on the HIV-1 CA would thus serve as a proof of measur-
able TRIM5α activity in vivo. To this end, we identiﬁed amino acids
under signiﬁcant positive selection in CA sequences from various
HIV-1 subtypes. We constructed viruses carrying the minor amino
acid represented at each position or an alanine mutation and
tested their susceptibility to different human allelic TRIM5α.Results
Identiﬁcation of positively selected sites in HIV-1 CA
A total of 113 curated clade B HIV-1 gag sequences were used
for detection of positive selection using Bayes Empirical Bayes
analysis. Separate analyses were run on 244 sequences from other
viral clades. HIV-1 CA was globally under strong purifying selec-
tion with Ka/Ks ratios ranging from 0.13 to 0.18 for the various
subtypes. However, we identiﬁed 6 amino acids under signiﬁcant
positive selection (posterior probability40.95) in the N-terminal
and C-terminal domains of clade B HIV-1, and 4 additional
residues in other clades (Table 1 and Fig. 1A): L6 (in β-hairpin);
A14 (between β-hairpin and helix 1); L83 (in helix 4); I91 (in
Cyclophilin A (CypA) binding loop); N120 and I124 (between helix
6 and 7); T148 (in interdomain linker); T171 (in helix 8); N183 (in
helix 9); T210 (between helix 10 and 11) and G225 (in unstruc-
tured part). In addition, H87, that has been associated with
modulation of TRIM5α activity (Hatziioannou et al., 2004a; Ikeda
et al., 2004; Owens et al., 2004) and identiﬁed in multiple
subtypes with posterior probabilities of 0.702 in subtype B and
0.668 in nonBC subtypes (Fig. 1A), had a posterior probability of
0.984 under the M7/M8 model, and it was retained for subsequent
analyses. In many cases, the consensus at these positions reﬂects
the ancestral HIV-1 M and the consensus SIVcpz residues (Table 1)
suggesting that those residues were already ﬁxed in the virus
transmitted to humans. Most study positions mapped to described
CTL and T-helper epitopes (http://www.hiv.lanl.gov/content/immu
nology/products.html) (Table 1) and position L6 has been asso-
ciated with selection pressure exerted by KIR (Alter et al., 2011).
Determinants of TRIM5α recognition localize in the N-terminal
domain of HIV-1 CA constituting a binding interface on the outer
CA lattice (Ganser-Pornillos et al., 2011; Hatziioannou et al., 2004a;
Owens et al., 2003). We mapped each positively selected position
onto the structure of CA in its hexameric form (PDB: 3H4E)
(Pornillos et al., 2009). Apart from positions 6 and 14, the study
positions were not found at binding interfaces of the hexamer.
Additionally, most of the positively selected positions were not
part of well-deﬁned secondary structure elements, with the
exception of positions 6 and 171 (Fig. 1B). Five of the identiﬁed
residues (L6, H87, I91, N120, I124) belong to structures exposed at
the surface of CA, i.e., the β-hairpin, the CypA binding loop and theloop between helix 6 and helix 7, or in proximity (A14 and L83)
(Fig. 1A, B). The three exposed structures in the N-terminus of CA
were reported to modulate TRIM5α restriction of HIV-1
(Hatziioannou et al., 2004a; Kuroishi et al., 2009; Maillard et al.,
2011), SIV (Kono et al., 2010) and N-tropic murine leukemia virus
(N-MLV) (Lassaux et al., 2005; Maillard et al., 2007; Ohkura et al.,
2011). Four residues (T148, T171, N183, G225) localize in the C
terminus of CA. Amino acid replacements in the C-terminus of CA
that impact the stability of the viral core may affect TRIM5α
sensitivity (Shi and Aiken, 2006; Zhao et al., 2011).
Characterization of recombinant viruses
To test the importance of positively selected sites of HIV-1 CA
on viral ﬁtness and TRIM5α-mediated restriction, we built 17
recombinant viruses carrying an alanine or a minor amino acid
represented in subtype B at the study position in N- and C-termini
(Table 1). Of note, some alanine mutations existed naturally as
minor variants in subtype B or other subtypes while four alanine
mutants (L83A; H87A; I124A; N183A) are unobserved in nature.
The control virus carried the common residue at the ten CA
positions.
p24 titers of minor variants ranged from 12% (T148A) to 186%
(I91V), and the infectious titers ranged from 10% (T148A) to 365%
(I91V) compared to the control virus (Fig. 1C). Thus, with the
exception of T148A and T171A viruses (having 10- and 5-fold
lower titers than control virus respectively), minor CA variants had
no major deleterious defects in 293T used as producer cells and in
CrFK as target cells. Three viruses with alanine mutations (not
observed as minor variants), L83A, I124A and N183A displayed a
decrease in both p24 and infectious titers. In particular, I124A
mutant, but not the minor variant I124V, displayed a 10-fold
reduction of p24 production and a 100-fold decrease of infectivity
indicating a major defect. Infectious titers were not correlated to
the frequency of the minor amino acid in the population (data not
shown).
Restriction by human and rhesus allelic TRIM5α variants
The sensitivity of recombinant viruses to TRIM5α-mediated
restriction was assessed by infection of CrFK stable lines expres-
sing the most common human allelic TRIM5α (H43, R136, G249,
H419) or a restrictive rhesus TRIM5α variant, referred to as
TRIM5TFP in (Kirmaier et al., 2010) (Fig. 2A, B). Consistent with
previous observations in CrFK cells (Hatziioannou et al., 2004b;
Rahm et al., 2011; Sebastian et al., 2006), human TRIM5α margin-
ally restricted the control CA HIV-1 with approximately two-fold
effect (Fig. 2B). Of note, all TRIM5α variants blocked N-MLV
infection; human H43Y TRIM5α was the least active. All recombi-
nant viruses were at least equally blocked, with some minor
variants, speciﬁcally L6M, I91V, T171A, G225A and the H87A
mutant, reaching four to 6-fold restriction (Fig. 2C). Rhesus
macaque TRIM5α strongly inhibited all HIV-1 viruses; the L6A
variant was the least restricted (Fig. 2D).
We next tested the restriction mediated by four frequent
human TRIM5α variants that carry non-synonymous polymorph-
isms: RING domain H43Y, coiled-coil R136Q, intervening sequence
G249D, and the v3 variant H419Y (Goldschmidt et al., 2006;
Javanbakht et al., 2006; Sawyer et al., 2006) (Fig. 2E–H). These
allelic variants were less active (R136Q4H419Y4G249D4H43Y)
than the common human TRIM5α. As previously described
(Goldschmidt et al., 2006; Javanbakht et al., 2006; Sawyer et al.,
2006), the H43Y variant was inactive against all HIV-1 constructs
(Fig. 2E). No viral construct singly escaped from one or more
TRIM5α alleles compared to other CA constructs.
Table 1
Sites of the HIV-1 CA under positive selective pressure.
Sitesa Structural locationb Amino acid contentc Posterior probabilityd Ancestral referencee Epitopesf Mutantsg
Capsid Gag Subtype B Subtype C nonBC HIV-1 M SIVcpzPtt
L6 138 β-Hairpin L:75.2% L:83.1% A:53.4% 0.984 (B) L6 A6 CTL L6Ah
I:18.6% I:5.2% L:42.5% 0.999 (C) T-helper L6M
M:6.2% A:4.1% Y:1.4% KIR
H:2.3% I:1.4%
S:2.3% M:1.3%
V:1.2%
P:1.2%
M:0.6%
A14 146 Interdomain β-hairpin- helix 1 A:70.8% A:72.5% A:53.4% 1 (C) A14 A14 CTL A14P
P:26.5% P:17.5% S:28.7% 1 (nonBC) P14
S:2.7% S:7.0% P:9.6%
N:1.8% N:5.5%
T:0.6% T:1.4%
K:0.6% V:1.4%
L83 215 Helix 4 L:88.4% L:80.7% L:80.5% 0.97 (B) L83 L83 CTL
V:10.7% V:8.8% V:5.6% 1 (C) T-helper L83Ai
L83V
M:0.9% I:4.1% M:6.9% 0.593 (nonBC)
T:4.1% T:5.6%
M:2.3% I:1.4%
H87 219 CypA loop H:80.4% H:84.8% H:71.9% 0.702 (B) H87 H87 CTL H87Ai
Q:19.6% Q:11.1% Q:26.7% 0.668 (nonBC) T-helper H87Q
P:4.1% P:1.4%
I91 223 CypA loop I:73.2% I:49.1% I:72.6% 1 (B and C) I91 I91 CTL I91A
V:23.2% V:39.1% V:20.5% 0.942 (nonBC) T-helper I91V
A:1.8% N:4.7% F:2.7%
N:0.9% A:3.5% P:1.4%
H:0.9% M:1.2% A:1.4%
T:1.2% N:1.4%
H:0.6%
Y:0.6%
N120 252 Interdomain helix 6–helix 7 N:59.8% S:56.7% S:68.5% 1 (B and C) S120 A120 T-helper N120Ah
S:20.5% G:17.4% G:28.8% 0.965 (nonBC) N120H
H:17.0% N:17.0% N:2.7%
G:0.9% A:5.9%
Q:0.9% H:1.2%
Y:0.9% R:0.6%
T:0.6%
D:0.6%
I124 256 Interdomain helix 6–helix 7 I:93.8% V:50.8% I:78.1% 0.989 (C) I124 I124 CTL I124Ai
V:4.4% I:48.0% V:21.9% V124 T-helper I124V
T:1.8% M:1.2%
T148 280 Interdomain linker T:69.0% V:94.7% V:100.0% 1 (B) V148 V148 CTL T148A
V:13.3% S:1.2% T-helper
S:8.0% T:2.9%
I:6.2% A:0.6%
A:3.5% Q:0.6%
T171 303 Helix 8 T:96.4% T:93.0% T:79.5% 0.988 (nonBC) T171 T171 CTL T171Ah
V:3.6% V:3.5% A:12.3% T-helper
C:1.7% V:6.8%
A:1.2% C:1.4%
I:0.6%
N183 315 Helix 9 N:97.3% N:97% N:49.4% 0.996 (nonBC) N183 N183 CTL N183Ai
T:0.9% G:2.4% G:47.9% T-helper
H:0.9% D:0.6% S:2.7%
G:0.9%
G225 357 Unstructured G:75.2% G:47.4% G:52.1% 1 (B and C) G225 S225 CTL G225A
S:21.2% S:52.0% S:46.6% 0.993 (nonBC)
A:2.7% A:0.6% Q:1.3%
H:0.9%
The analysis of 357 HIV-1 CA sequences from different subtypes (B, C and other) identiﬁed 10 sites under positive selection detected by Bayes Empirical Bayes (BEB) analysis
using the M2a model. H87 variants were included based on previous reports and M7/M8 analyses.
a Site of the HIV-1 CA under positive selection according to the subtype B reference and corresponding numbering in Gag.
b Structural location of the sites according to Gamble et al. (1996, 1997). CypA: Cyclophilin A.
c Amino acid frequency of the site residue according to subtype B (113 sequences), C (171 sequences) or other (73 sequences). The minor amino acid in subtype B
considered for in vitro reconstruction is represented in bold.
d Probability value upon data analysis for each subtype indicated in brackets using a maximum likelihood tree.
e The corresponding residues in the capsids of the ancestral HIV-1 group M and SIVcpz are indicated for each study position. A consensus gag was built from ﬁfteen
SIVcpz sequences originating from Pan troglodytes troglodytes subspecies.
f HIV-1 CA sites correspond to CD8 T cell (CTL) and CD4 T cell (T-helper) epitopes based on the HIV Immunology database provided on the Los Alamos National
Laboratory (http://www.hiv.lanl.gov/content/immunology/products.html). The KIR epitope was described in Alter et al. (2011).
g Mutation of the residue under positive selection with the minor variant or an alanine built in a B subtype CA background (from HIV-1NL4.3).
h Alanine variants that were observed in non-B subtypes.
i Alanine variants that were not observed naturally in any subtype.
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Fig. 1. Positive selection, structural position and viral titers of HIV-1 CA mutants. A. Amino acids of HIV-1 CA under positive selection. X axis: amino acid numbering.
Y axis: vertical lines correspond to the value of the posterior probability; residues with a signiﬁcant posterior probability (40.95) correspond to positively selected positions.
The secondary structure of CA is shown below the graph: cylinders show the position of α-helices and the box shows the position of the β-hairpin. The N-terminal domain is
represented by the gray line, the C-terminal domain is symbolized by the pink line, the CypA binding loop is shown in orange. Except for L6 and T171, none of the positively
selected positions occur in the middle of well-deﬁned secondary structure elements. B. Mapping of the positively selected positions on the structure of HIV-1 CA (PDB:
3H4E). The N-terminal domain is shown in gray and the C-terminal domain in pink. The CypA binding loop is shown in orange. Cyan spheres represent the different
positively selected positions. Position 14 is displayed with a red sphere to indicate that a cysteine was used at this position in the crystallized protein. C. p24 and infectious
titers of HIV-1 CA mutants. Titers of VSV-G pseudotyped GFP-reporter viruses were determined by ELISA detection of p24 HIV-1 CA protein (using polyclonal antibodies).
Results are presented as the percent of p24 concentration (pg/ml) for each mutant virus compared to the control CA-containing virus set to 100%. Infectious titers were
determined on the same viral stocks by infection of wild-type CrFK cells using serial dilution of viral supernatants in duplicate. Two days after infection, the percent of
GFP-positive cells was measured by ﬂow cytometry, thereby providing infectious titers in transducing units per millimeter (TU/ml) of virus. Results are presented as the
percent of infectious titer (TU/ml) for each mutant virus compared to the virus with control CA set to 100%. Error bars represent the standard deviation from the mean of two
independent viral productions. Stars indicate viruses carrying non-natural alanine mutations.
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The HIV-1 CA is highly conserved, and in vitro mutations of
conserved residues generally result in impaired particle produc-
tion or infectivity (Ganser-Pornillos et al., 2004). We analyzed
amino acids under selective pressure in CA sequences from HIV-1
infected individuals and identiﬁed six positions in clade B, and
four additional sites in other clades to be under signiﬁcant positive
selection. Recombinant CA viruses carrying minor amino acid
variants at these sites were competent for viral particle production
and infection. All viral constructs were highly sensitive to the
inhibition by the prototypical rhesus macaque TRIM5TFP and
modestly inhibited by several human allelic TRIM5α variants.
However, we did not observe unique CA viral variants selectively
escaping restriction from the human allelic TRIM5α tested. In
agreement with previous reports TRIM5α H43Y was impaired
(Goldschmidt et al., 2006; Javanbakht et al., 2006; Sawyer et al.,
2006). We interpret these data as indicating that the majority of
circulating strains represent an optimum of adaptation to human
TRIM5α. Indeed, many of the majority residues are already present
in the ancestral HIV-1M CA and SIVcpzPtt.
Interestingly, viral constructs carrying some minority variants
(L6M, H87A, I91V, T171A, G225A) were slightly more—not less—
restricted than the control CA virus. L6 lies in the β-hairpin;
mutations of this exposed structure have been previously asso-
ciated with modest changes in susceptibility to human TRIM5α
(then referred as Ref1) restriction (Hatziioannou et al., 2004a). H87
and I91 reside in the CypA binding loop, where the cellular CypA
interacts with HIV-1 CA (Luban, 2007). This loop is a determinant
region of TRIM5α speciﬁcity (Hatziioannou et al., 2004a; Kootstra
et al., 2003; Owens et al., 2004; Ylinen et al., 2005). H87Q
mutation was associated with reduced susceptibility to rhesus
TRIM5α (2- to 3-fold effect) in the presence of CypA in the target
cells (Ikeda et al., 2004; Owens et al., 2004; Pacheco et al., 2010).
In our dataset, H87Q mutation provided a limited beneﬁt (1.7-fold)
to HIV-1 infection in the presence of rhesus TRIM5α, but no escape
from human allelic TRIM5α variants. In contrast, the H87A mutant
and I91V increased HIV-1 sensitivity to human TRIM5α. It remains
unclear how T171A and G225A mutations in the C-terminal
domain of CA affect TRIM5α restriction. One possible explanation
is that these variants modify the stability of the core favoring
accelerated uncoating triggered by TRIM5α. Thus, major residues
of HIV-1 CA represent adaptation to TRIM5α while minor residues
may be selected against (purifying selection) in humans.
What are then the forces that result in signs of positive
selection at those residues? L6, H87, I91, T171, and G225 map to
recognized CTL epitopes: L6 (VV9 epitope); H87 and I91 (B7-HA9
epitope), T171 (A24-RL11 epitope) and G225 (GL9 epitope). Muta-
tions H87Q and I91V correspond to compensatory mutations for
the common CTL-escape T110N mutation (T242N in Gag) in the
TW10 epitope restricted by Bn57:01 that inﬂict a cost in viral
ﬁtness (Brockman et al., 2007; Martinez-Picado et al., 2006).Fig. 2. Restriction of HIV-1 CA mutants by human and rhesus TRIM5α variants. (A) Weste
rhesus macaque TRIM5α, the common human TRIM5α variant and four allelic forms of h
HA tag or β-actin. Control cells contain an empty pLPCX vector. (B) Infection of CrFK ex
G249D, H419Y) and rhesus macaque TRIM5α (TRIM5TFP allele) using 5000 pg equivalent o
N-MLV GFP virus. The percentage of infected cells was measured by ﬂow cytometry two
bars represent the standard error of the mean from duplicates. (C–H) Restriction activity
TRIM5α, (D) rhesus macaque TRIM5α (TRIM5TFP allele), (E) human H43Y TRIM5α, (F) h
Duplicate infections were performed using 5000 pg equivalent of p24 of each HIV-1 repo
infected cells was measured by ﬂow cytometry 2 days post-infection. The fold restriction
GFP-positive cells for CrFK controls cells by the percent of GFP-positive cells for CrFK-
restriction obtained for the common human TRIM5α. Black bar: virus with control CA;
subtypes; white bars: viruses carrying non-natural alanine mutations. Error bars represen
infectivity of the mutant virus I124A did not allow sufﬁcient readout to quantify the re
similar results were obtained in two independent experiments.Position T110 itself was not identiﬁed as harboring positive
selected variants; however 29 T110N variants were identiﬁed in
this study. The selective pressure posed by the acquired immunity
might lead to escape mutants that render the virus more suscep-
tible to human TRIM5α in vivo, partially explaining their large
ﬁtness cost. This scenario has been proposed by Battivelli et al.
(2011) who reported that recombinant viruses carrying gag from
clinical subtype B isolates were more sensitive to human TRIM5α
because of multiple CTL-escape and compensatory mutations in
CypA binding loop, TW10 epitope (helix 6) and KK10 epitope
(helix 7) of HIV-1 CA (Battivelli et al., 2011).
We investigated positions in HIV-1 CA that were positively
selected at statistically signiﬁcant level, though this does not cover
all the mutational space. Since the initial decision to build the
identiﬁed residues, we have extended clade B evolutionary analy-
sis to 635 clade B CA sequences (Snoeck et al., 2011). This larger
dataset conﬁrmed L6, L83, I91, N120 and T148 as residues under
positive selection, and identiﬁed two more residues, G116 and
L136, that are not included in the present work. Thus, our study
does not exclude the possibility of additional escape CA sites, rare
variants, or combination of variants resulting in escape. At position
R100 in HIV-1 CA, we only identiﬁed three R100T and one R100S
variant strains. This position corresponds to R97 in SIVsm, where
R97S represents an escape mutant from rhesus TRIM5α (Kirmaier
et al., 2010). HIV-1 CA R100S, that was previously built (Owens
et al., 2004), infected human and monkey cells expressing endo-
genous TRIM5α as efﬁciently as WT CA virus. Context speciﬁc
effects could be an issue for non-clade B residues built in a clade B
background. However, 4 of 5 residues discussed above to be
associated with increased susceptibility to TRIM5α represented
clade B minority species in a clade B CA context.
We also limited the study to well recognized human TRIM5
polymorphisms. Genome-wide association analyses did not iden-
tify additional common variants inﬂuencing HIV-1 infection in the
TRIM5 locus; however, other rare alleles may exist (Fellay et al.,
2007; Pereyra et al., 2010).Conclusions
The majority of CA sequences in HIV-1 clade B circulating in the
human population reﬂect optimal adaptation to human TRIM5α.
The modest restriction consistently observed in vitro may not
translate into relevant activity in vivo; in fact, there is no agree-
ment on differences in disease progression among individuals
carrying the various alleles despite documented differences in
in vitro activity. However, while different human TRIM5α alleles
may not impose further escape at population level; it may
contribute to restriction in the context of escape from the acquired
immunity.rn blot analysis of HA-tagged TRIM5α and β-actin in stable CrFK cell lines expressing
uman TRIM5α (H43Y, R136Q, G249D, H419Y) using antibodies directed against the
pressing the common human TRIM5α, four human TRIM5α variants (H43Y, R136Q,
f p24 of the control CA HIV-1 reporter GFP virus and comparable infectious dose of
days post-infection. Control cells were transduced with empty pLPCX vector. Error
expressed as fold changes after infection of CrFK expressing (C) the common human
uman R136Q TRIM5α, (G) human G249D TRIM5α, and (H) human H419Y TRIM5α.
rter GFP virus carrying mutations in the CA as indicated on X-axis. The percentage of
activity (i.e. inhibition of viral infection) was determined by dividing the percent of
TRIM5α cells. CA mutants are organized on X-axes in decreasing order of the fold
gray bars: viruses carrying mutations naturally observed in B, C and other (nonBC)
t the standard error of the mean from duplicates. n.d.: not determined; the reduced
striction activity by rhesus TRIM5α. Results from a single experiment are shown;
N. Rahm et al. / Virology 441 (2013) 162–170168Materials and methods
Sequence analysis
HIV-1 CA sequences from subtype B, and non-B subtypes were
retrieved from the Los Alamos database (http://www.hiv.lanl.gov/
content/index) for identiﬁcation of positively selected sites. Max-
imum likelihood trees were built for each subtype using the
HKY85 substitution model implemented in Mega v5 with esti-
mated ts/tv ratio. Bayes Empirical Bayes analysis implemented in
PAML v4.5 applied the M2a to identify amino acids under positive
selection. All residues identiﬁed under positive selection were
conﬁrmed in model M7/M8. For in vitro reconstruction of CA
minor variants in subtype B, we built clade B variants with
a frequency of 2.7–26.5%. We avoided rare mutants that could
result from sequencing errors. The ancestral group M HIV-1 gag
sequence was retrieved from Los Alamos website (http://www.hiv.
lanl.gov/content/sequence/NEWALIGN/align.html). Fifteen SIVcpz
gag from Pan troglodytes troglodytes (SIVcpzPtt) from the Los
Alamos repository were used to build a consensus SIVcpzPtt gag
sequence.Molecular modeling
The X-ray structure of HIV-1 CA in its hexameric form was used
for structural modeling (PDB: 3H4E) (Pornillos et al., 2009). In the
experimental structure, a cysteine is found at position 14 making a
disulﬁde bridge with its neighbor in the hexamer. Histidine is
found at position 120 in the published CA structure, while we used
a reference strain containing asparagine at this position in all
experiments. Finally, position 225 is located in a disordered region
that is not resolved in the structure and therefore could not be
modeled.Cell lines and stable lines
Human embryonic kidney 293T cells and Crandell feline
kidney (CrFK) cells were maintained in Dulbecco's modiﬁed Eagle
medium (DMEM) supplemented with 10% heat-inactivated
fetal calf serum, 2 mM glutamine, and antibiotics (100 U/ml of
penicillin and 100 mg/ml of streptomycin). pLPCX vectors encoding
HA-tagged human TRIM5α variants and rhesus macaque TRIM5α,
as well as puromycin resistance, were previously described
(Goldschmidt et al., 2006; Rahm et al., 2011). 293T cells were
cotransfected with pLPCX or each pLPCX–TRIM5α plasmid, the
packaging MLV Gag–Pol plasmid, and the VSV-G plasmid using
polyethylenimine (Polysciences). Supernatants were harvested
48 h post-transfection, ﬁltered (0.45 mm), concentrated (Centricon
units, Millipore) and used to transduce 106 CrFK cells in the
presence of 10 mg/ml of polybrene. After 72 h, CrFK cells were
selected in the presence of 5 mg/ml of puromycin. The expression
of TRIM5α from CrFK stable cell lines was conﬁrmed by western
blot using anti-HA antibodies.Western blots
Whole-cell lysates of CrFK cells were prepared in RIPA buffer
(50 mM Tris–HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5%
sodium deoxycholate) supplemented with Complete Mini protease
inhibitor cocktail (Roche) and centrifuged at 12,000g for 10 min.
The equivalent of 10 mg total protein was subjected to SDS-PAGE
and immunoblotted with rat monoclonal anti-HA antibody
(Roche) and mouse monoclonal anti-β-actin (Sigma).Recombinant viruses
The sequence of gag from a pNL4.3Δenv proviral clone was
inserted into a cloning vector and single mutations were intro-
duced in the CA sequence by site-directed mutagenesis using the
QuickChange protocol (Stratagene). The sequence of NL4-3 carries
a H120 that was modiﬁed to 120 N to reﬂect the consensus
sequence prior to introducing subsequent mutations. Mutated
gag fragments were cloned back into a pNL4.3-based HIV-1 Gag–
Pol vector. The resulting recombinant Gag–Pol vectors were used
to produce viruses by co-transfection of 293T with an HIV-1 GFP
genomic vector (pSIN.cPPT.CMV.GFP.WPRE) and VSV-G envelope
vector using calcium phosphate. Transfection medium was
replaced by fresh medium 20 h post-transfection. Viral super-
natants were harvested 48 h after transfection and ﬁltered
through 0.45 mm ﬁlters. Viral production was assessed by p24
quantiﬁcation by ELISA (Innogenetics). For determination of infec-
tious titers, 4104 CrFK cells were infected with serial dilutions of
viral supernatant in 48-well plates and GFP-positive cells were
quantiﬁed by ﬂuorescence-activated cell sorter (FACS) analysis two
days after infection. If required, viral supernatants were concen-
trated by using Centricon centrifugal ﬁlter devices (Millipore).
Infectivity assays
CrFK stable cell lines expressing the various TRIM5α were
infected by spinoculation of 5000 pg (p24 equivalent) of concen-
trated virus onto 5104 cells in 48-well plates for 1 h at 1500 g in
the presence of 10 mg/ml polybrene. Spinoculation allowed use of
less virus to maintain standard single stocks for the infection of
18 viruses in 7 cell lines in duplicate (252 conditions). Virus-
containing medium was removed and replaced by fresh medium
after spinoculation. Two days after infection, GFP-positive cells
were quantiﬁed by FACS analysis.Funding
This work was supported by the Swiss National Science
Foundation (Grant 31003A_132863/1, www.snf.ch).Author contributions
NR, AC and AT conceived the study.
NR, MO and RM performed experiments.
JS, DG and PJM performed analyses.
NR and AT wrote the main draft, edited by all authors.Acknowledgments
We thank Kunlin Zhang for preliminary analyses and Miguel
Munoz for technical advice.
References
Alter, G., Heckerman, D., Schneidewind, A., Fadda, L., Kadie, C.M., Carlson, J.M.,
Oniangue-Ndza, C., Martin, M., Li, B., Khakoo, S.I., Carrington, M., Allen, T.M.,
Altfeld, M., 2011. HIV-1 adaptation to NK-cell-mediated immune pressure.
Nature 476 (7358), 96–100.
Battivelli, E., Lecossier, D., Matsuoka, S., Migraine, J., Clavel, F., Hance, A.J., 2010.
Strain-speciﬁc differences in the impact of human TRIM5alpha, different
TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on
the infectivity of HIV-1. J. Virol. 84 (21), 11010–11019.
Battivelli, E., Migraine, J., Lecossier, D., Yeni, P., Clavel, F., Hance, A.J., 2011. Gag
cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to
human TRIM5alpha, linking intrinsic and acquired immunity. J. Virol. 85 (22),
11846–11854.
N. Rahm et al. / Virology 441 (2013) 162–170 169Brockman, M.A., Schneidewind, A., Lahaie, M., Schmidt, A., Miura, T., Desouza, I.,
Ryvkin, F., Derdeyn, C.A., Allen, S., Hunter, E., Mulenga, J., Goepfert, P.A., Walker,
B.D., Allen, T.M., 2007. Escape and compensation from early HLA-B57-mediated
cytotoxic T-lymphocyte pressure on human immunodeﬁciency virus type 1 Gag
alter capsid interactions with cyclophilin A. J. Virol. 81 (22), 12608–12618.
Fellay, J., Shianna, K.V., Ge, D., Colombo, S., Ledergerber, B., Weale, M., Zhang, K.,
Gumbs, C., Castagna, A., Cossarizza, A., Cozzi-Lepri, A., De Luca, A., Easterbrook, P.,
Francioli, P., Mallal, S., Martinez-Picado, J., Miro, J.M., Obel, N., Smith, J.P.,
Wyniger, J., Descombes, P., Antonarakis, S.E., Letvin, N.L., McMichael, A.J.,
Haynes, B.F., Telenti, A., Goldstein, D.B., 2007. A whole-genome association study
of major determinants for host control of HIV-1. Science 317 (5840), 944–947.
Gamble, T.R., Vajdos, F.F., Yoo, S., Worthylake, D.K., Houseweart, M., Sundquist, W.I.,
Hill, C.P., 1996. Crystal structure of human cyclophilin A bound to the
amino-terminal domain of HIV-1 capsid. Cell 87 (7), 1285–1294.
Gamble, T.R., Yoo, S., Vajdos, F.F., von Schwedler, U.K., Worthylake, D.K., Wang, H.,
McCutcheon, J.P., Sundquist, W.I., Hill, C.P., 1997. Structure of the
carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science
278 (5339), 849–853.
Ganser-Pornillos, B.K., Chandrasekaran, V., Pornillos, O., Sodroski, J.G., Sundquist, W.
I., Yeager, M., 2011. Hexagonal assembly of a restricting TRIM5alpha protein.
Proc. Natl. Acad. Sci. USA 108 (2), 534–539.
Ganser-Pornillos, B.K., von Schwedler, U.K., Stray, K.M., Aiken, C., Sundquist, W.I.,
2004. Assembly properties of the human immunodeﬁciency virus type 1 CA
protein. J. Virol. 78 (5), 2545–2552.
Goldschmidt, V., Bleiber, G., May, M., Martinez, R., Ortiz, M., Telenti, A., 2006. Role of
common human TRIM5alpha variants in HIV-1 disease progression. Retro-
virology 3, 54.
Goulder, P.J., Watkins, D.I., 2008. Impact of MHC class I diversity on immune control
of immunodeﬁciency virus replication. Nat. Rev. Immunol. 8 (8), 619–630.
Hatziioannou, T., Cowan, S., Von Schwedler, U.K., Sundquist, W.I., Bieniasz, P.D.,
2004a. Species-speciﬁc tropism determinants in the human immunodeﬁciency
virus type 1 capsid. J Virol 78 (11), 6005–6012.
Hatziioannou, T., Perez-Caballero, D., Yang, A., Cowan, S., Bieniasz, P.D., 2004b.
Retrovirus resistance factors Ref1 and Lv1 are species-speciﬁc variants of
TRIM5alpha. Proc. Natl. Acad. Sci. USA 101 (29), 10774–10779.
Henn, M.R., Boutwell, C.L., Charlebois, P., Lennon, N.J., Power, K.A., Macalalad, A.R.,
Berlin, A.M., Malboeuf, C.M., Ryan, E.M., Gnerre, S., Zody, M.C., Erlich, R.L.,
Green, L.M., Berical, A., Wang, Y., Casali, M., Streeck, H., Bloom, A.K., Dudek, T.,
Tully, D., Newman, R., Axten, K.L., Gladden, A.D., Battis, L., Kemper, M., Zeng, Q.,
Shea, T.P., Gujja, S., Zedlack, C., Gasser, O., Brander, C., Hess, C., Gunthard, H.F.,
Brumme, Z.L., Brumme, C.J., Bazner, S., Rychert, J., Tinsley, J.P., Mayer, K.H.,
Rosenberg, E., Pereyra, F., Levin, J.Z., Young, S.K., Jessen, H., Altfeld, M., Birren, B.
W., Walker, B.D., Allen, T.M., 2012. Whole genome deep sequencing of HIV-1
reveals the impact of early minor variants upon immune recognition during
acute infection. PLoS Pathog. 8 (3), e1002529.
Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., Markowitz, M.,
1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1
infection. Nature 373 (6510), 123–126.
Holmes, E.C., 2003. Error thresholds and the constraints to RNA virus evolution.
Trends Microbiol. 11 (12), 543–546.
Ikeda, Y., Ylinen, L.M., Kahar-Bador, M., Towers, G.J., 2004. Inﬂuence of gag on
human immunodeﬁciency virus type 1 species-speciﬁc tropism. J. Virol. 78 (21),
11816–11822.
Javanbakht, H., An, P., Gold, B., Petersen, D.C., O'Huigin, C., Nelson, G.W., O'Brien, S.J.,
Kirk, G.D., Detels, R., Buchbinder, S., Donﬁeld, S., Shulenin, S., Song, B., Perron, M.
J., Stremlau, M., Sodroski, J., Dean, M., Winkler, C., 2006. Effects of human
TRIM5alpha polymorphisms on antiretroviral function and susceptibility to
human immunodeﬁciency virus infection. Virology 354 (1), 15–27.
Kaumanns, P., Hagmann, I., Dittmar, M.T., 2006. Human TRIM5alpha mediated
restriction of different HIV-1 subtypes and Lv2 sensitive and insensitive HIV-2
variants. Retrovirology 3, 79.
Kirmaier, A., Wu, F., Newman, R.M., Hall, L.R., Morgan, J.S., O'Connor, S., Marx, P.A.,
Meythaler, M., Goldstein, S., Buckler-White, A., Kaur, A., Hirsch, V.M., Johnson,
W.E., 2010. TRIM5 suppresses cross-species transmission of a primate immu-
nodeﬁciency virus and selects for emergence of resistant variants in the new
species. PLoS Biol. 8 (8), e1000462.
Kono, K., Song, H., Yokoyama, M., Sato, H., Shioda, T., Nakayama, E.E., 2010. Multiple
sites in the N-terminal half of simian immunodeﬁciency virus capsid
protein contribute to evasion from rhesus monkey TRIM5alpha-mediated
restriction. Retrovirology 7, 72.
Kootstra, N.A., Munk, C., Tonnu, N., Landau, N.R., Verma, I.M., 2003. Abrogation of
postentry restriction of HIV-1-based lentiviral vector transduction in simian
cells. Proc. Natl. Acad. Sci. USA 100 (3), 1298–1303.
Kuroishi, A., Saito, A., Shingai, Y., Shioda, T., Nomaguchi, M., Adachi, A., Akari, H.,
Nakayama, E.E., 2009. Modiﬁcation of a loop sequence between alpha-helices 6
and 7 of virus capsid (CA) protein in a human immunodeﬁciency virus type 1 (HIV-
1) derivative that has simian immunodeﬁciency virus (SIVmac239) vif and CA
alpha-helices 4 and 5 loop improves replication in cynomolgus monkey cells.
Retrovirology 6, 70.
Lassaux, A., Sitbon, M., Battini, J.L., 2005. Residues in the murine leukemia
virus capsid that differentially govern resistance to mouse Fv1 and human
Ref1 restrictions. J. Virol. 79 (10), 6560–6564.
Letvin, N.L., Rao, S.S., Monteﬁori, D.C., Seaman, M.S., Sun, Y., Lim, S.Y., Yeh,
W.W., Asmal, M., Gelman, R.S., Shen, L., Whitney, J.B., Seoighe, C., Lacerda, M.,
Keating, S., Norris, P.J., Hudgens, M.G., Gilbert, P.B., Buzby, A.P., Mach, L.V., Zhang, J.,
Balachandran, H., Shaw, G.M., Schmidt, S.D., Todd, J.P., Dodson, A., Mascola, J.R.,Nabel, G.J., 2011. Immune and genetic correlates of vaccine protection against
mucosal infection by SIV in monkeys. Sci. Transl. Med. 3 (81), 81ra36.
Li, X., Gold, B., O'HUigin, C., Diaz-Griffero, F., Song, B., Si, Z., Li, Y., Yuan, W., Stremlau, M.,
Mische, C., Javanbakht, H., Scally, M., Winkler, C., Dean, M., Sodroski, J., 2007.
Unique features of TRIM5alpha among closely related human TRIM family
members. Virology 360 (2), 419–433.
Li, Y., Li, X., Stremlau, M., Lee, M., Sodroski, J., 2006. Removal of arginine 332 allows
human TRIM5alpha to bind human immunodeﬁciency virus capsids and to
restrict infection. J. Virol. 80 (14), 6738–6744.
Lim, S.Y., Rogers, T., Chan, T., Whitney, J.B., Kim, J., Sodroski, J., Letvin, N.L., 2010.
TRIM5alpha modulates immunodeﬁciency virus control in rhesus monkeys.
PLoS Pathog. 6 (1), e1000738.
Liu, F.L., Qiu, Y.Q., Li, H., Kuang, Y.Q., Tang, X., Cao, G., Tang, N.L., Zheng, Y.T., 2011. An
HIV-1 resistance polymorphism in TRIM5alpha gene among Chinese intrave-
nous drug users. J. Acquir. Immune Deﬁc. Syndr. 56 (4), 306–311.
Luban, J., 2007. Cyclophilin A, TRIM5, and resistance to human immunodeﬁciency
virus type 1 infection. J. Virol. 81 (3), 1054–1061.
Maillard, P.V., Reynard, S., Serhan, F., Turelli, P., Trono, D., 2007. Interfering residues
narrow the spectrum of MLV restriction by human TRIM5alpha. PLoS Pathog. 3
(12), e200.
Maillard, P.V., Zoete, V., Michielin, O., Trono, D., 2011. Homology-based identiﬁca-
tion of capsid determinants that protect HIV1 from human TRIM5alpha
restriction. J. Biol. Chem. 286 (10), 8128–8140.
Mansky, L.M., 1998. Retrovirus mutation rates and their role in genetic variation.
J. Gen. Virol. 79 (Pt 6), 1337–1345.
Martinez-Picado, J., Prado, J.G., Fry, E.E., Pfafferott, K., Leslie, A., Chetty, S.,
Thobakgale, C., Honeyborne, I., Crawford, H., Matthews, P., Pillay, T., Rousseau, C.,
Mullins, J.I., Brander, C., Walker, B.D., Stuart, D.I., Kiepiela, P., Goulder, P., 2006.
Fitness cost of escape mutations in p24 Gag in association with control of human
immunodeﬁciency virus type 1. J. Virol. 80 (7), 3617–3623.
Meddows-Taylor, S., Papathanasopoulos, M.A., Kuhn, L., Meyers, T.M., Tiemessen, C.T.,
2004. Detection of human immunodeﬁciency virus type 1 envelope peptide-
stimulated T-helper cell responses and variations in the corresponding regions of
viral isolates among vertically infected children. Virus Genes 28 (3), 311–318.
Nakajima, T., Nakayama, E.E., Kaur, G., Terunuma, H., Mimaya, J.I., Ohtani, H., Mehra, N.,
Shioda, T., Kimura, A., 2009. Impact of novel TRIM5alpha variants, Gly110Arg and
G176del, on the anti-HIV-1 activity and the susceptibility to HIV-1 infection. AIDS
23 (16), 2091–2100.
Newman, R.M., Hall, L., Connole, M., Chen, G.L., Sato, S., Yuste, E., Diehl, W., Hunter, E.,
Kaur, A., Miller, G.M., Johnson, W.E., 2006. Balancing selection and the evolution of
functional polymorphism in Old World monkey TRIM5alpha. Proc. Natl. Acad. Sci.
USA 103 (50), 19134–19139.
Ohkura, S., Goldstone, D.C., Yap, M.W., Holden-Dye, K., Taylor, I.A., Stoye, J.P., 2011.
Novel escape mutants suggest an extensive TRIM5alpha binding site spanning
the entire outer surface of the murine leukemia virus capsid protein. PLoS
Pathog. 7 (3), e1002011.
Owens, C.M., Song, B., Perron, M.J., Yang, P.C., Stremlau, M., Sodroski, J., 2004.
Binding and susceptibility to postentry restriction factors in monkey cells are
speciﬁed by distinct regions of the human immunodeﬁciency virus type
1 capsid. J. Virol. 78 (10), 5423–5437.
Owens, C.M., Yang, P.C., Gottlinger, H., Sodroski, J., 2003. Human and simian
immunodeﬁciency virus capsid proteins are major viral determinants of early,
postentry replication blocks in simian cells. J Virol 77 (1), 726–731.
Pacheco, B., Finzi, A., Stremlau, M., Sodroski, J., 2010. Adaptation of HIV-1 to cells
expressing rhesus monkey TRIM5alpha. Virology 408 (2), 204–212.
Paul, S., Piontkivska, H., 2010. Frequent associations between CTL and T-Helper
epitopes in HIV-1 genomes and implications for multi-epitope vaccine designs.
BMC Microbiol. 10, 212.
Pereyra, F., Jia, X., McLaren, P.J., Telenti, A., de Bakker, P.I., Walker, B.D., The
International HIV Controllers Study, 2010. The major genetic determinants of
HIV-1 control affect HLA class I peptide presentation. Science 330 (6010),
1551–1557.
Pham, Q.T., Bouchard, A., Grutter, M.G., Berthoux, L., 2010. Generation of human
TRIM5alpha mutants with high HIV-1 restriction activity. Gene Ther. 17 (7),
859–871.
Pornillos, O., Ganser-Pornillos, B.K., Kelly, B.N., Hua, Y., Whitby, F.G., Stout, C.D.,
Sundquist, W.I., Hill, C.P., Yeager, M., 2009. X-ray structures of the hexameric
building block of the HIV capsid. Cell 137 (7), 1282–1292.
Price, H., Lacap, P., Tuff, J., Wachihi, C., Kimani, J., Ball, T.B., Luo, M., Plummer, F.A.,
2010. A TRIM5alpha exon 2 polymorphism is associated with protection from
HIV-1 infection in the Pumwani sex worker cohort. AIDS 24 (12), 1813–1821.
Rahm, N., Telenti, A., 2012. The role of tripartite motif family members in mediating
susceptibility to HIV-1 infection. Curr. Opin. HIV AIDS.
Rahm, N., Yap, M., Snoeck, J., Zoete, V., Munoz, M., Radespiel, U., Zimmermann, E.,
Michielin, O., Stoye, J.P., Ciufﬁ, A., Telenti, A., 2011. Unique spectrum of activity
of prosimian TRIM5alpha against exogenous and endogenous retroviruses.
J. Virol. 85 (9), 4173–4183.
Rambaut, A., Posada, D., Crandall, K.A., Holmes, E.C., 2004. The causes and
consequences of HIV evolution. Nat. Rev. Genet. 5 (1), 52–61.
Richardson, M.W., Carroll, R.G., Stremlau, M., Korokhov, N., Humeau, L.M., Silvestri,
G., Sodroski, J., Riley, J.L., 2008. Mode of transmission affects the sensitivity of
human immunodeﬁciency virus type 1 to restriction by rhesus TRIM5alpha.
J. Virol. 82 (22), 11117–11128.
Richman, D.D., Wrin, T., Little, S.J., Petropoulos, C.J., 2003. Rapid evolution of the
neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci.
USA 100 (7), 4144–4149.
N. Rahm et al. / Virology 441 (2013) 162–170170Sanjuan, R., Borderia, A.V., 2011. Interplay between RNA structure and protein
evolution in HIV-1. Mol. Biol. Evol. 28 (4), 1333–1338.
Sawyer, S.L., Wu, L.I., Akey, J.M., Emerman, M., Malik, H.S., 2006. High-frequency
persistence of an impaired allele of the retroviral defense gene TRIM5alpha in
humans. Curr. Biol. 16 (1), 95–100.
Sebastian, S., Sokolskaja, E., Luban, J., 2006. Arsenic counteracts human immuno-
deﬁciency virus type 1 restriction by various TRIM5 orthologues in a cell type-
dependent manner. J. Virol. 80 (4), 2051–2054.
Shi, J., Aiken, C., 2006. Saturation of TRIM5 alpha-mediated restriction of HIV-1
infection depends on the stability of the incoming viral capsid. Virology 350 (2),
493–500.
Snoeck, J., Fellay, J., Bartha, I., Douek, D.C., Telenti, A., 2011. Mapping of positive
selection sites in the HIV-1 genome in the context of RNA and protein structural
constraints. Retrovirology 8, 87.
Sokolskaja, E., Berthoux, L., Luban, J., 2006. Cyclophilin A and TRIM5alpha
independently regulate human immunodeﬁciency virus type 1 infectivity in
human cells. J. Virol. 80 (6), 2855–2862.
Song, B., Javanbakht, H., Perron, M., Park, D.H., Stremlau, M., Sodroski, J., 2005.
Retrovirus restriction by TRIM5alpha variants from Old World and New World
primates. J. Virol. 79 (7), 3930–3937.
Speelmon, E.C., Livingston-Rosanoff, D., Li, S.S., Vu, Q., Bui, J., Geraghty, D.E., Zhao, L.
P., McElrath, M.J., 2006. Genetic association of the antiviral restriction factor
TRIM5alpha with human immunodeﬁciency virus type 1 infection. J. Virol. 80
(5), 2463–2471.
Stremlau, M., Owens, C.M., Perron, M.J., Kiessling, M., Autissier, P., Sodroski, J.,
2004a. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection
in Old World monkeys. Nature 427 (6977), 848–853.Stremlau, M., Owens, C.M., Perron, M.J., Kiessling, M., Autissier, P., Sodroski, J.,
2004b. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection
in Old World monkeys. Nature 427 (6977), 848–853.
Telenti, A., 2005. Adaptation, co-evolution, and human susceptibility to HIV-1
infection. Infect. Genet. Evol. 5 (4), 327–334.
van Manen, D., Rits, M.A., Beugeling, C., van Dort, K., Schuitemaker, H., Kootstra, N.
A., 2008. The effect of Trim5 polymorphisms on the clinical course of HIV-1
infection. PLoS Pathog. 4 (2), e18.
Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-Gonzalez, J.F.,
Salazar, M.G., Kilby, J.M., Saag, M.S., Komarova, N.L., Nowak, M.A., Hahn, B.H.,
Kwong, P.D., Shaw, G.M., 2003. Antibody neutralization and escape by HIV-1.
Nature 422 (6929), 307–312.
Woo, J., Robertson, D.L., Lovell, S.C., 2010. Constraints on HIV-1 diversity from
protein structure. J. Virol. 84 (24), 12995–13003.
Ylinen, L.M., Keckesova, Z., Wilson, S.J., Ranasinghe, S., Towers, G.J., 2005. Differ-
ential restriction of human immunodeﬁciency virus type 2 and simian
immunodeﬁciency virus SIVmac by TRIM5alpha alleles. J. Virol. 79 (18),
11580–11587.
Zhao, G., Ke, D., Vu, T., Ahn, J., Shah, V.B., Yang, R., Aiken, C., Charlton, L.M.,
Gronenborn, A.M., Zhang, P., 2011. Rhesus TRIM5alpha disrupts the HIV-1
capsid at the inter-hexamer interfaces. PLoS Pathog. 7 (3), e1002009.
Zhuang, J., Jetzt, A.E., Sun, G., Yu, H., Klarmann, G., Ron, Y., Preston, B.D., Dougherty,
J.P., 2002. Human immunodeﬁciency virus type 1 recombination: rate, ﬁdelity,
and putative hot spots. J. Virol. 76 (22), 11273–11282.
